Demand has broadened across independent fronts: growth is now coming from several distinct, currently-producing sources
The model's full reasoning — Q3 2018 call → NOWe need answer only YES or NO. Need evaluate transcript. Management describes multiple distinct current revenue engines? Let's parse. Company Precipio. On call, Ilan discusses commercial side: Liquid Biopsy (ICP), Pathology Services, new technologies IV-Cell and HemeScreen. Need see if each already producing real current business, and breadth recent/building. ICP: product development, panels, Perkin Elmer partnership co-marketing. Revenue potential 2019 estimated several hundreds to several million. Is ICP currently producing real revenue? They launched tests, but on call they talk about product development, partnership, go-to-market strategies. They don't explicitly say ICP current revenue in Q3. They say "revenue potential" and "will continue to expand". Perkin Elmer agreement is first step, not yet revenue? They estimate 2019 revenues. So ICP is not described as already producing real current business? Maybe they have tests in lab? But no concrete current revenue. They mention "our first ICP test" launched a year ago, now 5 panels. But no current revenue figures. So ICP is a front but maybe not "already producing real current business" in this call? They say "product line will continue to expand" and "revenue potential". So not count. Pathology Services: revenues from pathology services growing close to 50% from previous quarter. 10-member sales team, pipeline, conversion. Expect exceed $1 million per quarter by mid-2019. This is real current business. One engine. IV-Cell: proprietary cytogenetics media. They say commercialization process proceeded, interested parties received samples and tested. "We believe we're making great strides towards realization of value" and "looking forward to sharing exciting news". Not yet revenue? It's in trial, samples, not paying activity. So no. HemeScreen: launched in lab only two weeks ago, already received numerous orders from physicians. "Since launch of test in our lab, only two weeks ago, we've already received numerous orders -- we've already run numerous orders received from physicians." This is real current business, albeit very new. Revenue potential $1 million in 2019. So HemeScreen is a distinct engine, new, already producing orders. But is it "genuinely different in kind" from pathology services? HemeScreen is a test run in their CLIA lab, a proprietary technology. Pathology services also lab services.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| E | Eni S.p.A. | Q1 2024 | 2024-04-24 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PSFE | Paysafe Limited | Q4 2023 | 2024-03-07 | C+ |
| FRPH | FRP Holdings, Inc. | Q4 2023 | 2024-03-07 | C+ |
| GTLB | GitLab Inc. | Q4 2024 | 2024-03-04 | C+ |
| INTR | Inter & Co, Inc. | Q4 2023 | 2024-02-08 | B+ |
| TBLA | Taboola.com Ltd. | Q3 2023 | 2023-11-08 | B+ |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ANGO | AngioDynamics, Inc. | Q1 2024 | 2023-10-04 | B |
| CTLP | Cantaloupe, Inc. | Q4 2023 | 2023-09-06 | B+ |
| KMDA | Kamada Ltd. | Q2 2023 | 2023-08-16 | B+ |
| ZOM | Zomedica Corp. | Q2 2023 | 2023-08-10 | C |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| INTT | inTEST Corporation | Q2 2023 | 2023-08-04 | A |
| FOUR | Shift4 Payments, Inc. | Q2 2023 | 2023-08-03 | B+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| PERI | Perion Network Ltd. | Q2 2023 | 2023-08-02 | A |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| EDU | New Oriental Education & Technology Grou | Q3 2023 | 2023-04-19 | B |
| ISRG | Intuitive Surgical, Inc. | Q4 2022 | 2023-01-24 | C |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| UGRO | urban-gro, Inc. | Q1 2022 | 2022-05-13 | D |
| XMTR | Xometry, Inc. | Q1 2022 | 2022-05-11 | B+ |
| CLAR | Clarus Corporation | Q1 2022 | 2022-05-09 | B |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| ABNB | Airbnb, Inc. | Q1 2022 | 2022-05-03 | B+ |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| WSC | WillScot Mobile Mini Holdings Corp. | Q4 2021 | 2022-02-25 | B+ |
| LMND | Lemonade, Inc. | Q4 2021 | 2022-02-24 | D |
| SNOW | Snowflake Inc. | Q3 2022 | 2021-12-01 | A |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| BRAG | Bragg Gaming Group Inc. | Q3 2021 | 2021-11-08 | B+ |
| ENV | Envestnet, Inc. | Q3 2021 | 2021-11-08 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| CROX | Crocs, Inc. | Q3 2021 | 2021-10-21 | B+ |
| DG | Dollar General Corporation | Q2 2021 | 2021-08-26 | A |
| ZIM | ZIM Integrated Shipping Services Ltd. | Q2 2021 | 2021-08-18 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| Z | Zillow Group, Inc. | Q2 2021 | 2021-08-05 | B |
| NOV | NOV Inc. | Q2 2021 | 2021-07-28 | C+ |
| STRA | Strategic Education, Inc. | Q2 2021 | 2021-07-28 | C |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| BCO | The Brink's Company | Q3 2018 | 2018-10-24 | C |
| NDLS | Noodles & Company | Q3 2018 | 2018-10-23 | B+ |
| AUDC | AudioCodes Ltd. | Q3 2018 | 2018-10-23 | A |
| YEXT | Yext, Inc. | Q2 2019 | 2018-08-30 | C+ |
| TNC | Tennant Company | Q2 2018 | 2018-07-25 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| ST | Sensata Technologies Holding plc | Q2 2017 | 2017-07-25 | B+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| HUBB | Hubbell Incorporated | Q2 2017 | 2017-07-25 | B+ |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| PPSI | Pioneer Power Solutions, Inc. | Q4 2016 | 2017-03-10 | B |
| ABR | Arbor Realty Trust, Inc. | Q4 2016 | 2017-03-03 | B+ |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| LGND | Ligand Pharmaceuticals Incorporated | Q4 2016 | 2017-02-23 | C+ |
| PYPL | PayPal Holdings, Inc. | Q4 2016 | 2017-01-26 | B+ |
| PNFP | Pinnacle Financial Partners, Inc. | Q2 2016 | 2016-07-20 | B |
| BX | Blackstone Inc. | Q1 2016 | 2016-04-21 | B |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
GDRX · Q2 2022 → YESThe question is about whether management describes the company's CURRENT growth as being carried by SEVERAL DISTINCT, INDEPENDENT SOURCES AT THE SAME TIME — at least three genuinely different engines,...YES The transcript shows management describing current growth as carried by multiple distinct engines: prescription transactions (still the core but with recent challenges), subscriptions revenue (82% YoY growth), and Pharma Manufacturer Solutions (more than doubled YoY). They explicitly frame the diversification as a recent development, noting that other offerings now make up 30% of revenue compared to 5% just three years ago, with several sources like subscriptions and pharma still having most of their contribution ahead due to significant TAM and low penetration. This breadth is presented as newly meaningful for the company, reflecting the early stage of these newer fronts rather than a long-standing diversified business.
TOUR · Q4 2017 → YESThe question is about whether management describes current growth being carried by several distinct, independent sources at the same time — at least three genuinely different engines — each already pr...YES Management describes current growth as carried by multiple distinct, independent engines that are already producing real revenue and activity: packaged tours (organized and self-guided), financial services and commissions, offline retail stores (18% of GMV in Q4 2017, launched 2016), direct procurement (40% of GM 2017), and corporate TMC services (more than 200% YoY growth). They explicitly note diversification of sales channels (online, mobile, loyalty, offline, B2B/corporate) and that the company was narrower until recently, with offline retail and corporate TMC expanding in 2016–2017 while local operators remain small but growing.
CYBR · Q3 2021 → YESThe question is about whether management describes current growth being carried by several distinct, independent sources at the same time — at least three genuinely different engines — each producing ...YES The transcript shows management describing current growth as driven by multiple distinct, independent engines operating simultaneously: record SaaS bookings and subscription ARR growth (131%), the Identity Security platform centered on Privileged Access Management (PAM) and Privilege Cloud with new logos over 230, EPM with another record quarter, Access and DevSecOps offerings, plus expansion across geographies (every region growing) and verticals (new logos in law firms, software, oil & gas, retailers, government). These are presented as real, current business with concrete metrics and customer examples, not plans.